The film features scenes where partners rotate, often involving multiple participants in a single room.
The MAPK/ERK cascade (RAS‑RAF‑MEK‑ERK) orchestrates critical cellular processes such as proliferation, differentiation, and survival. Aberrant activation—most commonly via KRAS, NRAS, or BRAF mutations—underpins the pathogenesis of >30 % of human cancers, including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma, and melanoma. While several MEK inhibitors (e.g., trametinib, binimetinib) have entered clinical practice, therapeutic efficacy is limited by dose‑dependent toxicities and rapid emergence of resistance (e.g., MAPK re‑activation, feedback loops). Consequently, there remains a pressing need for next‑generation MEK inhibitors with improved potency, selectivity, and pharmacologic properties. mukd-546
Male Sprague‑Dawley rats (n = 4 per group) received Mukd‑546 either intravenously (2 mg·kg⁻¹) or orally (10 mg·kg⁻¹). Plasma samples collected up to 24 h, quantified by LC‑MS/MS (LLOQ = 1 ng·mL⁻¹). PK parameters (C_max, AUC₀‑∞, t₁/₂, bioavailability) calculated using Phoenix WinNonlin. The film features scenes where partners rotate, often